Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $294.6 million.

  • Foghorn Therapeutics' Total Liabilities fell 1248.71% to $294.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $294.6 million, marking a year-over-year decrease of 1248.71%. This contributed to the annual value of $329.5 million for FY2024, which is 925.24% down from last year.
  • According to the latest figures from Q3 2025, Foghorn Therapeutics' Total Liabilities is $294.6 million, which was down 1248.71% from $302.9 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Total Liabilities ranged from a high of $422.9 million in Q4 2021 and a low of $104.3 million during Q2 2021
  • Over the past 5 years, Foghorn Therapeutics' median Total Liabilities value was $352.5 million (recorded in 2024), while the average stood at $325.1 million.
  • As far as peak fluctuations go, Foghorn Therapeutics' Total Liabilities skyrocketed by 29715.06% in 2022, and later tumbled by 1248.71% in 2025.
  • Over the past 5 years, Foghorn Therapeutics' Total Liabilities (Quarter) stood at $422.9 million in 2021, then fell by 4.29% to $404.8 million in 2022, then decreased by 10.29% to $363.1 million in 2023, then decreased by 9.25% to $329.5 million in 2024, then decreased by 10.59% to $294.6 million in 2025.
  • Its Total Liabilities was $294.6 million in Q3 2025, compared to $302.9 million in Q2 2025 and $320.3 million in Q1 2025.